Archives

CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients with Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

Melissa Johnson, Jordi Rodon Ahnert, Nehal Lakhani, Rachel E. Sanborn, Anthony El-Khoueiry, Navid Hafez, Hirva Mamdani, Valentina Boni, Henry Castro, Alison L. Hannah, Alexander Spira. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore virtual meeting, January 28-31, 2021.

Learn More

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of the Probody® Therapeutic (Pb-Tx) Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2-Negative Breast Cancer (mHR+/HER2− BC) and of CX-2009 as Monotherapy and in Combination Therapy With Pacmilimab (CX-072) in Metastatic Triple-Negative Breast Cancer (TNBC)

Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.

Learn More

Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.

Learn More

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

Learn More

Harnessing the Power of CytomX’s Probody® Technology to Drug the Undruggable

Alison L. Hannah, MD. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Utilizing Probody® Technology to Develop Therapeutics to Undruggable Targets

Bob Liu, Ph.D. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166

Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Development of a Probody Drug Conjugate (PDC) Targeting CD71 for the Treatment of Cancer

Presented at 10th Annual World Antibody Drug Conjugate Conference. London, United Kingdom March 4, 2020
Luc Desnoyers, Ph.D.

Learn More